

Peptic Ulcers (Gastrointestinal) - Drugs in Development, 2021

<https://marketpublishers.com/r/PCBEC9D244DEEN.html>

Date: November 2021

Pages: 77

Price: US\$ 2,000.00 (Single User License)

ID: PCBEC9D244DEEN

Abstracts

Peptic Ulcers (Gastrointestinal) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers - Drugs In Development, 2021, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 3, 5, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and

molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Peptic Ulcers - Overview
- Peptic Ulcers - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Peptic Ulcers - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Peptic Ulcers - Companies Involved in Therapeutics Development
- Addpharma Inc
- Axsome Therapeutics Inc
- CalyGene Biotechnology Inc
- Cinclus Pharma AG
- Daewoong Pharmaceutical Co Ltd
- Edenbridge Pharmaceuticals LLC
- FortuneRock (China) Ltd
- Hunan Mingrui Pharmaceutical Co Ltd
- Hunan Sailong Pharmaceutical Co Ltd
- Ilyang Pharmaceutical Co Ltd
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Korea Pharma Co Ltd
- Kukje Pharmaceutical Industry Co Ltd
- PharmaKing Co Ltd
- PharmGen Science Inc
- RaQualia Pharma Inc
- Sotex Pharm Firm
- XuanZhu Biological Technology Co Ltd
- Peptic Ulcers - Drug Profiles
- (meloxicam + esomeprazole) - Drug Profile
- Product Description

Mechanism Of Action
R&D Progress
AD-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
famotidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexuprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrrolate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-2150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IYIC-062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-3571 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

konolazan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaprazan glurate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKS-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabeprazole sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vonoprazan acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WRDN-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptic Ulcers - Dormant Projects

Peptic Ulcers - Discontinued Products

Peptic Ulcers - Product Development Milestones

Featured News & Press Releases

Oct 22, 2021: Sihuan Pharmaceutical Holdings Group: New Drug Application of Xuanzhu Biopharm's drug Anaprazole Sodium accepted by NMPA

Mar 12, 2020: Gastroesophageal reflux disease new drug K-cap, Helicobacter pylori eradication indication

Feb 13, 2020: Sihuan Pharmaceutical Holdings Group: Commencement of phase III clinical trial in the PRC for self-developed innovative patented drug Anaprazole Sodium

Apr 25, 2019: Sihuan Pharm's innovative digestive system drug Anaprazole Sodium achieved early completion of patient recruitment for phase II clinical trial in China

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies

Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Peptic Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Peptic Ulcers - Pipeline by Addpharma Inc, 2021
Peptic Ulcers - Pipeline by Axsome Therapeutics Inc, 2021
Peptic Ulcers - Pipeline by CalyGene Biotechnology Inc, 2021
Peptic Ulcers - Pipeline by Cinclus Pharma AG, 2021
Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Edenbridge Pharmaceuticals LLC, 2021
Peptic Ulcers - Pipeline by FortuneRock (China) Ltd, 2021
Peptic Ulcers - Pipeline by Hunan Mingrui Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Hunan Sailong Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Ilyang Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Korea Pharma Co Ltd, 2021
Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021
Peptic Ulcers - Pipeline by PharmaKing Co Ltd, 2021
Peptic Ulcers - Pipeline by PharmGen Science Inc, 2021
Peptic Ulcers - Pipeline by RaQualia Pharma Inc, 2021
Peptic Ulcers - Pipeline by Sotex Pharm Firm, 2021
Peptic Ulcers - Pipeline by XuanZhu Biological Technology Co Ltd, 2021
Peptic Ulcers - Dormant Projects, 2021
Peptic Ulcers - Dormant Projects, 2021 (Contd..1)
Peptic Ulcers - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peptic Ulcers, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Peptic Ulcers (Gastrointestinal) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/PCBEC9D244DEEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PCBEC9D244DEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970